A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children
Identifieur interne : 001248 ( Istex/Corpus ); précédent : 001247; suivant : 001249A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children
Auteurs : Ruth A. Karron ; Peter F. Wright ; Frances K. Newman ; Mamodikoe Makhene ; Juliette Thompson ; Roberta Samorodin ; Modena H. Wilson ; Edwin L. Anderson ; Mary Lou Clements ; Brian R. Murphy ; Robert B. BelsheSource :
- Journal of Infectious Diseases [ 0022-1899 ] ; 1995.
Abstract
The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (ca), temperature-sensitive (ts) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 104 or 105 TCID50 of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 102.2 pfu/mL. Virus present in respiratory specimens retained the ts phenotype, and each of 86 PIV-3 isolates tested retained both the ca and ts phenotypes. One dose of 105 TCID50 of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.
Url:
DOI: 10.1093/infdis/172.6.1445
Links to Exploration step
ISTEX:08904D8467172BCF456101291CE3C2FE59998F9BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children</title><author><name sortKey="Karron, Ruth A" sort="Karron, Ruth A" uniqKey="Karron R" first="Ruth A." last="Karron">Ruth A. Karron</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation><affiliation><mods:affiliation>Reprints or correspondence: Dr. Ruth A. Karron, Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Hampton House 125,624 N. Broadway, Baltimore, MD 21205.</mods:affiliation></affiliation></author><author><name sortKey="Wright, Peter F" sort="Wright, Peter F" uniqKey="Wright P" first="Peter F." last="Wright">Peter F. Wright</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Newman, Frances K" sort="Newman, Frances K" uniqKey="Newman F" first="Frances K." last="Newman">Frances K. Newman</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Makhene, Mamodikoe" sort="Makhene, Mamodikoe" uniqKey="Makhene M" first="Mamodikoe" last="Makhene">Mamodikoe Makhene</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Thompson, Juliette" sort="Thompson, Juliette" uniqKey="Thompson J" first="Juliette" last="Thompson">Juliette Thompson</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Samorodin, Roberta" sort="Samorodin, Roberta" uniqKey="Samorodin R" first="Roberta" last="Samorodin">Roberta Samorodin</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Wilson, Modena H" sort="Wilson, Modena H" uniqKey="Wilson M" first="Modena H." last="Wilson">Modena H. Wilson</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Anderson, Edwin L" sort="Anderson, Edwin L" uniqKey="Anderson E" first="Edwin L." last="Anderson">Edwin L. Anderson</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Clements, Mary Lou" sort="Clements, Mary Lou" uniqKey="Clements M" first="Mary Lou" last="Clements">Mary Lou Clements</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Belshe, Robert B" sort="Belshe, Robert B" uniqKey="Belshe R" first="Robert B." last="Belshe">Robert B. Belshe</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:08904D8467172BCF456101291CE3C2FE59998F9B</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1093/infdis/172.6.1445</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-XLTB2R20-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001248</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001248</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children</title><author><name sortKey="Karron, Ruth A" sort="Karron, Ruth A" uniqKey="Karron R" first="Ruth A." last="Karron">Ruth A. Karron</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation><affiliation><mods:affiliation>Reprints or correspondence: Dr. Ruth A. Karron, Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Hampton House 125,624 N. Broadway, Baltimore, MD 21205.</mods:affiliation></affiliation></author><author><name sortKey="Wright, Peter F" sort="Wright, Peter F" uniqKey="Wright P" first="Peter F." last="Wright">Peter F. Wright</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Newman, Frances K" sort="Newman, Frances K" uniqKey="Newman F" first="Frances K." last="Newman">Frances K. Newman</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Makhene, Mamodikoe" sort="Makhene, Mamodikoe" uniqKey="Makhene M" first="Mamodikoe" last="Makhene">Mamodikoe Makhene</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Thompson, Juliette" sort="Thompson, Juliette" uniqKey="Thompson J" first="Juliette" last="Thompson">Juliette Thompson</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Samorodin, Roberta" sort="Samorodin, Roberta" uniqKey="Samorodin R" first="Roberta" last="Samorodin">Roberta Samorodin</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Wilson, Modena H" sort="Wilson, Modena H" uniqKey="Wilson M" first="Modena H." last="Wilson">Modena H. Wilson</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Anderson, Edwin L" sort="Anderson, Edwin L" uniqKey="Anderson E" first="Edwin L." last="Anderson">Edwin L. Anderson</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Clements, Mary Lou" sort="Clements, Mary Lou" uniqKey="Clements M" first="Mary Lou" last="Clements">Mary Lou Clements</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Belshe, Robert B" sort="Belshe, Robert B" uniqKey="Belshe R" first="Robert B." last="Belshe">Robert B. Belshe</name><affiliation><mods:affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1995-12">1995</date><biblScope unit="vol">172</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1445">1445</biblScope><biblScope unit="page" to="1450">1450</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (ca), temperature-sensitive (ts) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 104 or 105 TCID50 of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 102.2 pfu/mL. Virus present in respiratory specimens retained the ts phenotype, and each of 86 PIV-3 isolates tested retained both the ca and ts phenotypes. One dose of 105 TCID50 of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.</div></front></TEI><istex><corpusName>oup</corpusName><keywords><teeft><json:string>vaccine</json:string><json:string>seronegative</json:string><json:string>parainfluenza</json:string><json:string>phenotype</json:string><json:string>tcid</json:string><json:string>attenuated</json:string><json:string>placebo</json:string><json:string>seronegative child</json:string><json:string>vaccinee</json:string><json:string>seropositive</json:string><json:string>vaccine virus</json:string><json:string>viral</json:string><json:string>belshe</json:string><json:string>antibody titer</json:string><json:string>parainfluenza virus type</json:string><json:string>placebo recipient</json:string><json:string>karron</json:string><json:string>seropositive child</json:string><json:string>mutant</json:string><json:string>young child</json:string><json:string>immunogenic</json:string><json:string>antibody response</json:string><json:string>immunogenicity</json:string><json:string>virus vaccine</json:string><json:string>parainfluenza virus</json:string><json:string>seronegative vaccinee</json:string><json:string>peak titer</json:string><json:string>nasal wash</json:string><json:string>titer</json:string><json:string>influenza</json:string><json:string>replication</json:string><json:string>febrile illness</json:string><json:string>candidate vaccine</json:string><json:string>reassortant virus vaccine</json:string><json:string>assay</json:string><json:string>virus</json:string><json:string>datum</json:string><json:string>immunization</json:string><json:string>nasal</json:string><json:string>vaccination</json:string><json:string>nasal wash specimen</json:string><json:string>infectious disease</json:string><json:string>human parainfluenza type</json:string><json:string>human parainfluenza virus type</json:string><json:string>saint louis university</json:string><json:string>otitis medium</json:string><json:string>clinical response</json:string><json:string>clin microbiol</json:string><json:string>rhesus monkey</json:string><json:string>immunization research</json:string><json:string>vaccine candidate</json:string><json:string>phenotypically stable</json:string></teeft></keywords><author><json:item><name>Ruth A. Karron</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string><json:string>Reprints or correspondence: Dr. Ruth A. Karron, Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Hampton House 125,624 N. Broadway, Baltimore, MD 21205.</json:string></affiliations></json:item><json:item><name>Peter F. Wright</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Frances K. Newman</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Mamodikoe Makhene</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Juliette Thompson</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Roberta Samorodin</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Modena H. Wilson</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Edwin L. Anderson</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Mary Lou Clements</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Brian R. Murphy</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Robert B. Belshe</name><affiliations><json:string>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</json:string></affiliations></json:item></author><arkIstex>ark:/67375/HXZ-XLTB2R20-5</arkIstex><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (ca), temperature-sensitive (ts) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 104 or 105 TCID50 of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 102.2 pfu/mL. Virus present in respiratory specimens retained the ts phenotype, and each of 86 PIV-3 isolates tested retained both the ca and ts phenotypes. One dose of 105 TCID50 of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.</abstract><qualityIndicators><score>7.124</score><pdfWordCount>4489</pdfWordCount><pdfCharCount>28261</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>581.04 x 770.94 pts</pdfPageSize><pdfWordsPerPage>748</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>false</refBibsNative><abstractWordCount>164</abstractWordCount><abstractCharCount>1123</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children</title><pmid><json:string>7594701</json:string></pmid><genre><json:string>research-article</json:string></genre><host><title>Journal of Infectious Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0022-1899</json:string></issn><eissn><json:string>1537-6613</json:string></eissn><publisherId><json:string>jid</json:string></publisherId><volume>172</volume><issue>6</issue><pages><first>1445</first><last>1450</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1995</json:string></date><geogName></geogName><orgName><json:string>Immunization Research, Johns Hopkins University School of Hygiene and Public Health</json:string><json:string>and Laboratory of Infectious Diseases, National Institute</json:string><json:string>Immunization Research, Department of International Health, School of Hygiene and Public Health</json:string><json:string>Medical Center</json:string><json:string>Johns Hopkins University</json:string><json:string>Vanderbilt University</json:string><json:string>Saint Louis University</json:string><json:string>Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee</json:string><json:string>National Institutes of Health</json:string><json:string>National Institutes of Health, Bethesda, Maryland</json:string><json:string>Joint Committee for Clinical Investigation of Johns Hopkins University School of Medicine</json:string><json:string>Louis VA Medical Center</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Peter F. Wright</json:string><json:string>K. Newman</json:string><json:string>Sharon Moore</json:string><json:string>Barbara Bums</json:string><json:string>Mary Lou</json:string><json:string>Brian R. Murphy</json:string><json:string>Juliette Thompson</json:string><json:string>Gretel Mills</json:string><json:string>H. Wilson</json:string><json:string>Anna Speaks</json:string><json:string>Sharon Tollefson</json:string><json:string>Edwin L. Anderson</json:string><json:string>Ruth A. Karron</json:string><json:string>Robert Chanock</json:string><json:string>Louis Potash</json:string><json:string>Roberta Samorodin</json:string><json:string>Martin Blair</json:string></persName><placeName><json:string>San Diego</json:string><json:string>Baltimore</json:string><json:string>MD</json:string><json:string>Chicago</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[1-5]</json:string><json:string>[16, 17, 31]</json:string><json:string>[1, 6-10]</json:string><json:string>[34, 35]</json:string><json:string>[6]</json:string><json:string>[14-18]</json:string><json:string>[33]</json:string><json:string>[17]</json:string><json:string>[17, 18]</json:string><json:string>[1,6]</json:string><json:string>[13-17]</json:string><json:string>[32]</json:string><json:string>[16]</json:string><json:string>[20]</json:string><json:string>[20-30]</json:string><json:string>[11, 12]</json:string><json:string>[21-30]</json:string><json:string>[18, 19]</json:string><json:string>[14-16]</json:string><json:string>[16, 17]</json:string><json:string>[7, 19]</json:string><json:string>[13]</json:string><json:string>Karron et al.</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/HXZ-XLTB2R20-5</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - microbiology</json:string><json:string>2 - infectious diseases</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - microbiology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1093/infdis/172.6.1445</json:string></doi><id>08904D8467172BCF456101291CE3C2FE59998F9B</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-XLTB2R20-5/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-XLTB2R20-5/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-XLTB2R20-5/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>The University of Chicago Press</publisher><availability><licence>© 1995 by The University of Chicago</licence></availability><date type="Copyright" when="1995">1995</date><date when="1995-12">1995</date></publicationStmt><notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children</title><author xml:id="author-0000" role="corresp"><persName><surname>Karron</surname><forename type="first">Ruth A.</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation><affiliation role="corresp">Reprints or correspondence: Dr. Ruth A. Karron, Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Hampton House 125,624 N. Broadway, Baltimore, MD 21205.</affiliation></author><author xml:id="author-0001"><persName><surname>Wright</surname><forename type="first">Peter F.</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0002"><persName><surname>Newman</surname><forename type="first">Frances K.</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0003"><persName><surname>Makhene</surname><forename type="first">Mamodikoe</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0004"><persName><surname>Thompson</surname><forename type="first">Juliette</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0005"><persName><surname>Samorodin</surname><forename type="first">Roberta</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0006"><persName><surname>Wilson</surname><forename type="first">Modena H.</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0007"><persName><surname>Anderson</surname><forename type="first">Edwin L.</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0008"><persName><surname>Clements</surname><forename type="first">Mary Lou</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0009"><persName><surname>Murphy</surname><forename type="first">Brian R.</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><author xml:id="author-0010"><persName><surname>Belshe</surname><forename type="first">Robert B.</forename></persName><affiliation><orgName type="institution">Center for Immunization Research</orgName><orgName type="department">Department of International Health</orgName><orgName type="department">School of Hygiene and Public Health</orgName><orgName type="department">Departments of Pediatrics and Medicine</orgName><orgName type="department">School of Medicine</orgName><orgName type="institution">Johns Hopkins University</orgName><address><addrLine>Baltimore</addrLine></address></affiliation><affiliation><orgName type="laboratory">Laboratory of Infectious Diseases</orgName><orgName type="institution">National Institute of Allergy and Infectious Diseases</orgName><orgName type="institution">National Institutes of Health</orgName><address><addrLine>Bethesda, Maryland</addrLine></address></affiliation><affiliation><orgName type="laboratory">Vaccine Evaluation Unit</orgName><orgName type="department">Department of Pediatrics</orgName><orgName type="institution">Vanderbilt University School of Medicine</orgName><address><addrLine>Nashville, Tennessee</addrLine></address></affiliation><affiliation><orgName type="institution">Center for Vaccine Development</orgName><orgName type="department">Division of Infectious Diseases</orgName><orgName type="department">Departments of Internal Medicine and Pediatrics</orgName><orgName type="institution">Saint Louis University</orgName><orgName type="institution">and St Louis VA Medical Center</orgName><address><addrLine>St. Louis, Missouri</addrLine></address></affiliation></author><idno type="istex">08904D8467172BCF456101291CE3C2FE59998F9B</idno><idno type="ark">ark:/67375/HXZ-XLTB2R20-5</idno><idno type="DOI">10.1093/infdis/172.6.1445</idno></analytic><monogr><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="hwp">jinfdis</idno><idno type="publisher-id">jid</idno><idno type="pISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1995-12">1995</date><biblScope unit="vol">172</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1445">1445</biblScope><biblScope unit="page" to="1450">1450</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract><p>The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (<hi rend="italic">ca</hi>), temperature-sensitive (<hi rend="italic">ts</hi>) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 10<hi rend="superscript">4</hi> or 10<hi rend="superscript">5</hi> TCID<hi rend="subscript">50</hi> of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 10<hi rend="superscript">2.2</hi> pfu/mL. Virus present in respiratory specimens retained the <hi rend="italic">ts</hi> phenotype, and each of 86 PIV-3 isolates tested retained both the <hi rend="italic">ca</hi> and <hi rend="italic">ts</hi> phenotypes. One dose of 10<hi rend="superscript">5</hi> TCID<hi rend="subscript">50</hi> of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.</p></abstract><textClass ana="subject"><keywords scheme="heading"><term>Major Articles</term></keywords></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2019-12-11">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-XLTB2R20-5/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="hwp">jinfdis</journal-id>
<journal-id journal-id-type="publisher-id">jid</journal-id>
<journal-title>Journal of Infectious Diseases</journal-title>
<abbrev-journal-title>J Infect Dis.</abbrev-journal-title>
<issn pub-type="ppub">0022-1899</issn>
<issn pub-type="epub">1537-6613</issn>
<publisher>
<publisher-name>The University of Chicago Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1093/infdis/172.6.1445</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Major Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Karron</surname>
<given-names>Ruth A.</given-names>
</name>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wright</surname>
<given-names>Peter F.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Newman</surname>
<given-names>Frances K.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Makhene</surname>
<given-names>Mamodikoe</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thompson</surname>
<given-names>Juliette</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Samorodin</surname>
<given-names>Roberta</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilson</surname>
<given-names>Modena H.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anderson</surname>
<given-names>Edwin L.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clements</surname>
<given-names>Mary Lou</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murphy</surname>
<given-names>Brian R.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Belshe</surname>
<given-names>Robert B.</given-names>
</name>
</contrib>
<aff><institution>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health</institution>, <institution>Departments of Pediatrics and Medicine, School of Medicine, Johns Hopkins University</institution>, <addr-line>Baltimore</addr-line></aff>
<aff><institution>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</institution>, <addr-line>Bethesda, Maryland</addr-line></aff>
<aff><institution>Vaccine Evaluation Unit, Department of Pediatrics, Vanderbilt University School of Medicine</institution>, <addr-line>Nashville, Tennessee</addr-line></aff>
<aff><institution>Center for Vaccine Development, Division of Infectious Diseases, Departments of Internal Medicine and Pediatrics, Saint Louis University, and St. Louis VA Medical Center</institution>, <addr-line>St. Louis, Missouri</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Reprints or correspondence: Dr. Ruth A. Karron, Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Hampton House 125,624 N. Broadway, Baltimore, MD 21205.</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>12</month>
<year>1995</year>
</pub-date>
<volume>172</volume>
<issue>6</issue>
<fpage>1445</fpage>
<lpage>1450</lpage>
<history>
<date date-type="received">
<day>7</day>
<month>5</month>
<year>1995</year>
</date>
<date date-type="rev-recd">
<day>1</day>
<month>8</month>
<year>1995</year>
</date>
</history>
<copyright-statement>© 1995 by The University of Chicago</copyright-statement>
<copyright-year>1995</copyright-year>
<abstract>
<p>The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (<italic>ca</italic>), temperature-sensitive (<italic>ts</italic>) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 10<sup>4</sup> or 10<sup>5</sup> TCID<sub>50</sub> of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 10<sup>2.2</sup> pfu/mL. Virus present in respiratory specimens retained the <italic>ts</italic> phenotype, and each of 86 PIV-3 isolates tested retained both the <italic>ca</italic> and <italic>ts</italic> phenotypes. One dose of 10<sup>5</sup> TCID<sub>50</sub> of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.</p>
</abstract>
</article-meta>
</front>
</article>
</istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Ruth A.</namePart><namePart type="family">Karron</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><affiliation>Reprints or correspondence: Dr. Ruth A. Karron, Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Hampton House 125,624 N. Broadway, Baltimore, MD 21205.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter F.</namePart><namePart type="family">Wright</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Frances K.</namePart><namePart type="family">Newman</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mamodikoe</namePart><namePart type="family">Makhene</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Juliette</namePart><namePart type="family">Thompson</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roberta</namePart><namePart type="family">Samorodin</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Modena H.</namePart><namePart type="family">Wilson</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Edwin L.</namePart><namePart type="family">Anderson</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mary Lou</namePart><namePart type="family">Clements</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Brian R.</namePart><namePart type="family">Murphy</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert B.</namePart><namePart type="family">Belshe</namePart><affiliation>Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Baltimore, Bethesda, Maryland, Nashville, Tennessee, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">1995-12</dateIssued><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><abstract>The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (ca), temperature-sensitive (ts) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 104 or 105 TCID50 of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 102.2 pfu/mL. Virus present in respiratory specimens retained the ts phenotype, and each of 86 PIV-3 isolates tested retained both the ca and ts phenotypes. One dose of 105 TCID50 of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.</abstract><note type="author-notes">Reprints or correspondence: Dr. Ruth A. Karron, Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Hampton House 125,624 N. Broadway, Baltimore, MD 21205.</note><relatedItem type="host"><titleInfo><title>Journal of Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>J Infect Dis.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0022-1899</identifier><identifier type="eISSN">1537-6613</identifier><identifier type="PublisherID">jid</identifier><identifier type="PublisherID-hwp">jinfdis</identifier><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>172</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1445</start><end>1450</end></extent></part></relatedItem><identifier type="istex">08904D8467172BCF456101291CE3C2FE59998F9B</identifier><identifier type="ark">ark:/67375/HXZ-XLTB2R20-5</identifier><identifier type="DOI">10.1093/infdis/172.6.1445</identifier><accessCondition type="use and reproduction" contentType="copyright">© 1995 by The University of Chicago</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource><recordOrigin>Converted from (version 1.2.0) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-XLTB2R20-5/record.json</uri></json:item></metadata><covers><json:item><extension>tiff</extension><original>true</original><mimetype>image/tiff</mimetype><uri>https://api.istex.fr/document/08904D8467172BCF456101291CE3C2FE59998F9B/covers/tiff</uri></json:item></covers><annexes><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-XLTB2R20-5/annexes.pdf</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001248 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001248 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:08904D8467172BCF456101291CE3C2FE59998F9B
|texte= A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children
}}
| This area was generated with Dilib version V0.6.33. |  |